| Website | archventure.com |
| Phone | 773 380 6600 |
| Employees | |
| Founded | 1986 |
| Total | $1.45B |
| I, 1989 | $9M |
| II, 1993 | $31M |
| III, 1996 | $107M |
| IV, 1999 | $175M |
| V, 2000 | $380M |
| VI, 2003 | $350M |
| VII, 2007 | $400M |
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories.
ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors.
| Company | Date | Round | Size | Participants |
| Groove Biopharma | 12/11 | Series B | $6M | 4 |
| Agios Pharmaceuticals | 11/11 | Series C | $78M | 4 |
| Siluria Technologies | 9/11 | Series B | $20M | 7 |
| Kythera Biopharmaceuticals | 9/11 | Series D | $37.4M | 7 |
| Shocking Technologies | 8/11 | Series C | $15.2M | 5 |
| Pulmatrix | 8/11 | Series B | $14M | 4 |
| Oncofactor Corporation | 8/11 | Series A | $2.1M | 6 |
| Sorbent Therapeutics | 6/11 | Series B | $36M | 5 |
| Semprius | 6/11 | Series C | $20M | 6 |
| bluebird bio | 4/11 | Unattributed | $30M | 5 |
| Univa | 1/11 | Unattributed | $7M | 6 |
| Acylin Therapeutics | 1/11 | Series A | $4.4M | 4 |
| Kilimanjaro Energy | 10/10 | Series A | 1 | |
| Siluria Technologies | 10/10 | Unattributed | $13.3M | 6 |
| Sorbent Therapeutics | 9/10 | Series B | $21.8M | 4 |
| Crystal IS | 8/10 | Series B | $4M | 4 |
| Ciespace | 8/10 | Series A | $4M | 2 |
| Bind Biosciences | 6/10 | Series C | $12.4M | 4 |
| Adesto Technologies | 6/10 | Unattributed | $3.5M | 4 |
| Mirina | 4/10 | Series A | $3.9M | 5 |
| Achaogen | 4/10 | Series C | $56M | 7 |
| Theraclone Sciences | 3/10 | Unattributed | $1.5M | 6 |
| Shocking Technologies | 2/10 | Series B | $8M | 5 |
| VentiRx Pharmaceuticals | 1/10 | Series A | $51.6M | 4 |
| Innovalight | 1/10 | Series D | $18M | 8 |
| Receptos | 11/09 | Series A | $25M | 4 |
| Fate Therapeutics | 11/09 | Series B | $30M | 6 |
| Pulmatrix | 11/09 | Series B | $30.2M | 4 |
| Cambrios Technologies | 11/09 | Series D | $14.5M | 14 |
| Innovalight | 10/09 | Unattributed | $15M | 7 |
| Shocking Technologies | 8/09 | Series B | $10M | 3 |
| Limerick BioPharma | 7/09 | Series C | $15M | 3 |
| Semprius | 6/09 | Series B | $6.4M | 5 |
| Elixir Pharmaceuticals | 5/09 | Series D | $12M | 5 |
| Lycera | 5/09 | Series A | $36M | 4 |
| Qwell Pharmaceuticals | 1/09 | Series A | $7M | 2 |
| Sapphire Energy | 9/08 | Series D | $35M | 2 |
| Limerick BioPharma | 6/08 | Unattributed | $15.2M | 3 |
| Sapphire Energy | 5/08 | Series C | $50M | 2 |
| Kythera Biopharmaceuticals | 5/08 | Series C | $30M | 9 |
| Univa UD | 5/08 | Series B | $8M | 5 |
| PhaseRx | 2/08 | Series A | $19M | 3 |
| KOTURA | 2/08 | Series C | $10M | 5 |
| MediaPhy | 2/08 | Unattributed | $7M | 2 |
| Fate Therapeutics | 11/07 | Series A | $12M | 4 |
| Allozyne | 10/07 | Series B | $30M | 5 |
| Xtera Communications | 8/07 | Unattributed | $52M | 3 |
| Semprius | 7/07 | Series A | $4.1M | 3 |
| Shocking Technologies | 4/07 | Series A | $7M | 2 |
| Impinj | 3/07 | Series E | $19M | 10 |
| Omeros | 2/07 | Series E | $63M | 8 |
| Variation Biotechnologies | 1/07 | Series A | $35.7M | 3 |
| Elixir Pharmaceuticals | 11/06 | Series C | $46M | 6 |
| Chiasma | 11/06 | Series C | $44M | 4 |
| Aveso | 10/06 | Series B | $6.25M | 3 |
| Achaogen | 10/06 | Series B | $26M | 5 |
| Crystal IS | 8/06 | Series B | $10.6M | 5 |
| Kythera Biopharmaceuticals | 7/06 | Series B | $30M | 6 |
| AmberWave | 7/06 | Series E | $25M | 5 |
| Nitronex | 6/06 | Unattributed | $21.8M | 6 |
| VLST Corporation | 6/06 | Series B | $55M | 7 |
| Impinj | 12/05 | Unattributed | $26.5M | 9 |
| Allozyne | 12/05 | Series A | $3.5M | 4 |
| nanosys | 11/05 | Series D | $41.5M | 16 |
| KOTURA | 9/05 | Series B | $13M | 4 |
| Univa UD | 8/05 | Series A | $8M | 4 |
| Cambrios Technologies | 2/05 | Series B | $12M | 8 |
| Ahura Scientific | 1/05 | Series B | $10M | 5 |
| Ensemble Discovery | 5/04 | Series A | $15M | 3 |
